Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sakar HealthcareNSE:SAKAR -1.89%60 Debt-to-EBITDA is 0.52 as of Mar. 2026, which is 71% below its 10-year median of 1.82. GuruFocus rates NSE:SAKAR with a GF Score™ of 60/100 and a GF Value™ of ₹565.75 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 678 Drug Manufacturers companies, Sakar Healthcare ranks better than 66.08% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sakar Healthcare's Debt-to-EBITDA or its related term are showing as below:
NSE:SAKAR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.64 Med: 1.82 Max: 3.19
Current: 0.78
During the past 11 years, the highest Debt-to-EBITDA Ratio of Sakar Healthcare was 3.19. The lowest was 0.64. And the median was 1.82.
NSE:SAKAR's Debt-to-EBITDA is ranked better than 66.08% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs NSE:SAKAR: 0.78
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sakar Healthcare Debt-to-EBITDA Related Terms
Sakar Healthcare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sakar Healthcare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakar Healthcare Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sakar Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Sakar Healthcare (NSE:SAKAR) has a Debt-to-EBITDA of 0.52 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sakar Healthcare. This is 71% below median its historical median of 1.82. Over the past decade, Sakar Healthcare's Debt-to-EBITDA has ranged from 0.64 to 3.19. According to the industry distribution chart, Sakar Healthcare ranks #230 out of 678 companies in the Drug Manufacturers industry, placing it in the top 33.9%.
Is Sakar Healthcare's Debt-to-EBITDA too high?
Sakar Healthcare's current Debt-to-EBITDA of 0.52 is 71% below median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 3.19. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Sakar Healthcare's value of 0.52 is 68.3% below this industry median. Based on the distribution chart, Sakar Healthcare ranks #230 out of 678 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sakar Healthcare ranks #230 out of 678 companies for Debt-to-EBITDA. This puts Sakar Healthcare in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Sakar Healthcare's value of 0.52 is 68.3% below this benchmark. Historically, Sakar Healthcare's own Debt-to-EBITDA has ranged from 0.64 to 3.19 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 1.64, Sakar Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sakar Healthcare's current Debt-to-EBITDA of 0.52 is 68.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sakar Healthcare. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakar Healthcare's current Debt-to-EBITDA is 0.52, which is 71% below median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹565.75, compared to a current price of ₹875.70 — trading 54.8% above its estimated fair value. The current Debt-to-EBITDA is 0.52, which is 71% below median its 10-year median of 1.82 and 68.3% below the Drug Manufacturers industry median of 1.64. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current Debt-to-EBITDA is 0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?
Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued.
The current stock price of ₹875.70 is trading 54.8% above its estimated GF Value™ of ₹565.75.
GuruFocus considers Sakar Healthcare to be Significantly Overvalued.
Key valuation signals for NSE:SAKAR:
Debt-to-EBITDA: 0.52 (71% below median its 10-year median of 1.82)
GF Value™: ₹565.75 vs. price of ₹875.70 (54.8% above fair value)
Industry Position: 68.3% below the Drug Manufacturers median (#230 of 678)
No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score
Get the complete analysis for NSE:SAKAR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAKAR has been successfully added to your 
